Baker Bros. Advisors’s aTyr Pharma ATYR Stock Holding History

Baker Bros. Advisors’s Portfolio ATYR Stock Details ATYR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-8,565	Closed	-$18.8K	–	113
2022 Q4	$18.8K	Sell	8,565 -192,796	-96%	-$455K	﹤0.01%	113
2022 Q3	$604K	Sell	201,361 -173,034	-46%	-$580K	﹤0.01%	103
2022 Q2	$1.06M	Sell	374,395 -250,605	-40%	-$906K	0.01%	101
2022 Q1	$3.34M	Hold	625,000	–	–	0.02%	96
2021 Q4	$4.67M	Hold	625,000	–	–	0.02%	95
2021 Q3	$5.67M	Buy	+625,000	New	+$3.74M	0.02%	91
2016 Q2	–	Sell	-152,686	Closed	-$8.42M	–	139
2016 Q1	$8.42M	Sell	152,686 -14,109	-8%	-$1.07M	0.09%	62
2015 Q4	$23M	Hold	166,795	–	–	0.19%	39
2015 Q3	$24M	Hold	166,795	–	–	0.22%	37
2015 Q2	$43.2M	Buy	+166,795	New	+$51.8M	0.38%	29

Other funds holding ATYR

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Tikvah Management Charlotte, North Carolina $323M AUM 69.61% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baker Bros. Advisors's ATYR Position: Q1 2023 in Review

Baker Bros. Advisors sold out of aTyr Pharma (ATYR) in Q1 2023, closing a stake of 8,565 shares — an estimated $18.8K sold.

Baker Bros. Advisors first reported a position in ATYR in Q2 2015 and held it in 10 quarters. The position peaked at $43.2M in Q2 2015. 37 funds tracked by Wall St. Rank hold ATYR as of Q1 2023.

Baker Bros. Advisors reported no remaining aTyr Pharma position as of Q1 2023 after selling out during the quarter.
Baker Bros. Advisors sold 8,565 aTyr Pharma shares in Q1 2023, an estimated $18.8K.
Baker Bros. Advisors first reported a position in aTyr Pharma in Q2 2015 and held it in 10 quarters.
Baker Bros. Advisors's aTyr Pharma position peaked at $43.2M in Q2 2015.
37 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2023.

Based on Baker Bros. Advisors's 13F filing for Q1 2023, filed 15 May 2023.